NYSE:PHR
Phreesia, Inc.
Phreesia offers a comprehensive digital identity verification platform that streamlines patient intake processes for healthcare organizations globally.
Key Metrics
Investment Thesis
Bull Case
Phreesia demonstrates strong top-line growth momentum with revenue expanding consistently over the past three years while improving its loss trajectory from -$176.1M to -$58.5M. The company maintains a healthy cash position with $84.2M in cash equivalents and positive operating cash flow that funds its expansion without heavy reliance on equity dilution. As healthcare providers prioritize digital transformation, Phreesia's entrenched market position offers significant upside potential if profitability can be achieved.
Bear Case
The company continues to operate at a substantial loss with net profit of -$58.5M and no path to clear its multi-billion dollar retained earnings deficit clearly visible. High capital expenditures of $8.7M combined with aggressive spending on marketing ($121.1M) and R&D ($117.4M) suggests that growth is being funded at unsustainable levels. Investors may face significant downside risk if the company cannot achieve breakeven operations before competitors erode its market share or if regulatory pressures increase compliance costs.
About Phreesia, Inc.
Phreesia is a leading healthcare technology platform that provides patient identity verification and data capture solutions to healthcare systems, payers, and life sciences companies. The company serves markets across the United States and internationally, offering digital onboarding tools that streamline patient registration while ensuring data privacy and compliance. Its key products include secure web forms, mobile apps, and APIs designed to reduce no-show rates and improve operational efficiency for healthcare providers.
Analysis
Management Discussion
Despite achieving revenue growth of approximately 18% year-over-year from $356.3M to $419.8M, the company reported a net loss of $58.5M for the latest period. Operating expenses totaling $411.7M significantly exceeded gross profit of $353.6M, resulting in an operating loss of $58.1M driven by substantial marketing and R&D investments. Cash flow from operations remained positive at $32.4M, providing some liquidity buffer against the accumulated retained earnings deficit of $801.5M.
Industry Overview
The healthcare technology sector is experiencing rapid digital transformation as providers seek to modernize patient engagement and reduce administrative burdens. Regulatory scrutiny around data privacy in healthcare continues to tighten, creating both barriers to entry and opportunities for compliant specialized platforms. The market favors solutions that can integrate seamlessly with legacy systems while providing measurable improvements in patient outcomes and operational efficiency.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $280.9M | $356.3M | $419.8M |
| Cost of Revenue | $58.9M | $61.0M | $66.2M |
| Gross Profit | $222.0M | $295.3M | $353.6M |
| Operating Expenses | $398.5M | $431.8M | $411.7M |
| Operating Income | $-176.6M | $-136.5M | $-58.1M |
| R&D | $91.2M | $112.3M | $117.4M |
| G&A | $80.4M | $79.9M | $76.6M |
| Marketing | $151.3M | $147.0M | $121.1M |
| Stock-Based Comp | $58.8M | $71.6M | $67.0M |
| D&A | $25.3M | $29.5M | $27.9M |
| Depreciation | $18.0M | $17.6M | $14.2M |
| Amortization | $1.4M | $2.4M | $3.5M |
| Other OpEx | $75.6M | $92.5M | $96.6M |
| Non-Operating Income | $889.0K | $1.1M | $2.3M |
| Interest Expense | $1.4M | $1.9M | — |
| Interest Income | — | — | $2.7M |
| Pre-Tax Income | $-175.7M | $-135.3M | $-55.8M |
| Income Tax | $483.0K | $1.5M | $2.7M |
| Continuing Ops | $-176.1M | $-136.9M | $-58.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-176.1M | $-136.9M | $-58.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-176.1M | $-136.9M | $-58.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $262.4M | $195.7M | $203.3M |
| Cash & Equivalents | $176.7M | $87.5M | $84.2M |
| Accounts Receivable | $51.4M | $64.9M | $73.6M |
| Prepaid Expenses | $10.7M | $14.5M | $15.9M |
| Other Current Assets | $23.7M | $28.8M | $29.6M |
| Long-Term Assets | $107.6M | $174.6M | $185.1M |
| Goodwill | $33.7M | $75.8M | $75.8M |
| Operating Leases | $569.0K | $266.0K | $1.5M |
| Other LT Assets | $73.3M | $98.5M | $107.8M |
| Total Assets | $370.1M | $370.3M | $388.4M |
| Current Liabilities | $79.0M | $110.1M | $114.0M |
| Accounts Payable | $10.8M | $8.5M | $5.6M |
| Current Leases | $934.0K | $393.0K | $964.0K |
| Deferred Revenue | $17.7M | $24.1M | $32.8M |
| Taxes Payable | $1.5M | — | — |
| Other Current Liab | $26.3M | $40.0M | $37.2M |
| Long-Term Liabilities | $3.2M | $8.8M | $9.6M |
| LT Operating Leases | $349.0K | $134.0K | $646.0K |
| Other LT Liab | $2.7M | $8.5M | $8.8M |
| Total Liabilities | $82.2M | $118.9M | $123.6M |
| Shareholders' Equity | $287.8M | $251.4M | $264.8M |
| Paid-In Capital | $927.0M | $1.04B | $1.11B |
| Retained Earnings | $-606.1M | $-743.0M | $-801.5M |
| AOCI | — | — | $-51.0K |
| Treasury Stock | $33.6M | — | — |
| Total L&E | $370.1M | $370.3M | $388.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-176.1M | $-136.9M | $-58.5M |
| Non-Cash Adjustments | $66.0M | $78.2M | $74.0M |
| Working Capital Changes | $20.1M | $26.3M | $16.9M |
| Cash from Operations | $-90.1M | $-32.4M | $32.4M |
| Capital Expenditures | $4.7M | $5.8M | $8.7M |
| Cash from Investing | $-26.2M | $-39.7M | $-24.1M |
| Cash from Financing | $-20.8M | $-17.1M | $-11.5M |
| FX Effect | $0 | $0 | $-106.0K |
| Net Change in Cash | $-137.1M | $-89.2M | $-3.3M |
| Beginning Cash | $313.8M | $176.7M | $87.5M |
| Ending Cash | $176.7M | $87.5M | $84.2M |
Frequently Asked Questions
How does Phreesia, Inc. make money?
The company generates revenue primarily through licensing fees and subscription contracts with healthcare systems, insurance payers, and life sciences firms. Additional streams include value-added services such as analytics dashboards, integration support, and specialized solutions for clinical trial recruitment and patient engagement programs.
What are the main risks for PHR?
The company faces margin compression risks due to intense competition from larger tech firms entering the healthcare identity verification space. Dependence on a concentrated client base in the US healthcare sector exposes revenue streams to regulatory changes and payer consolidation. Persistent operating losses and high cash burn rates could threaten liquidity if revenue growth slows or financing conditions deteriorate.
What is PHR's competitive advantage?
Phreesia possesses a robust proprietary database of verified patient identities that significantly reduces fraud and duplicate records in healthcare settings. The platform's seamless integration with existing electronic health record systems creates high switching costs for enterprise clients. Its extensive network of integrated third-party providers creates an ecosystem advantage that new entrants struggle to replicate.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.